Mediqstar, a South Korean company specializing in generative AI for CRO and tuberculosis diagnostics, has received funding from Genaxis. This investment will enable Mediqstar to enhance its business operations and accelerate its entry into global markets.

Established in September 2023, Mediqstar is leveraging generative AI to advance its AI Contract Research Organization (CRO) technology and develop the tuberculosis diagnostic kit, MycoScan.

The company’s AI-driven diagnostic kit simplifies and accelerates the tuberculosis detection process. Plans are underway to launch this product in Vietnam and other international markets starting next year. Despite the extensive time and capital typically required for AI technology development, Mediqstar is establishing a swift revenue stream through the sales of its diagnostic kits, ensuring stable research and development progression.

Tuberculosis remains a major cause of mortality globally, particularly in less developed countries. Mediqstar’s diagnostic kit reduces the number of required tests from three to one and cuts down the diagnosis time from 30 days to a mere seven days. This efficiency and cost-effectiveness make it a strong competitor in the global market.

Genaxis, the investing firm, praised Mediqstar: “With outstanding generative AI capabilities and a team of medical experts, Mediqstar is poised not only to succeed in the global market with its tuberculosis diagnostic kits but also to transform the paradigm of drug development through AI CRO.”

Mediqstar commented, “Beginning with the sales of our tuberculosis diagnostic kits, we aim to greatly enhance the efficiency of the costly and time-consuming clinical trial processes in the pharmaceutical industry through our generative AI-based AI CRO model.”